Page 1

Sr. No. Ipca Laboratories Limited Regd . Office : 48 , Kandivli Industrial Estate , Kandivli ( W ) , Mumbai 400 067 CIN : L24239MH1949PLC007837 Tel : +91 22 6647 4444 , E - mail : investors@ipca.com Website : www.ipca.com STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31 , 2020 | Revenue from operations Other Income Total Income ( I + II ) Particulars Unaudited ( Crores ) Year Ended Mar 31 , 2020 Audited Quarter Ended Dec 31 , 2020 Sept 30 , 2020 Unaudited Dec 31 , 2019 Unaudited Nine Months Ended Dec 31 , 2020 Unaudited Dec 31 , 2019 1315.22 1139.07 4098.24 15.65 15.00 17.63 42.33 51.39 64.69 1330.87 1312.77 1156.70 4140.57 3414.03 4432.12 1297.77 Unaudited 3362.64 4367.43 IV Expenses : a ) Cost of materials consumed 377.72 405.78 350.63 b ) Purchases of stock - in - trade 61.60 32.78 53.98 c ) Changes in inventories of finished goods , 28.08 ( 32.00 ) ( 23.08 ) 1146.23 127.75 7.42 1060.04 1431.10 153.80 204.65 ( 60.08 ) ( 155.05 ) work - in - progress and stock - in - trade d ) Employee benefits expense 230.03 239.09 217.72 711.04 642.91 870.79 e ) Finance costs 1.56 1.81 3.80 5.83 12.32 15.79 f ) Depreciation and amortisation expense 47.66 46.26 46.16 139.15 133.31 178.69 g ) Other expenses 268.96 291.96 274.38 808.86 843.93 1101.18 Total Expenses ( IV ) 1015.61 985.68 923.59 2946.28 2786.23 3647.15 > 5 5 Profit before exceptional items and tax ( III - IV ) 315.26 327.09 233.11 1194.29 627.80 784.97 Exceptional items VII Profit before tax ( V - VI ) 315.26 327.09 233.11 1194.29 627.80 784.97 VIII Tax Expense - Current tax - Short ( Excess ) provision of earlier years 55.10 52.10 40.78 208.70 109.80 137.98 - Deferred tax liability / ( asset ) including MAT credit 0.19 ( 0.69 ) ( 4.30 ) ( 3.70 ) ( 6.70 ) ( 5.47 ) IX Profit for the period from continuing operations ( VII - VIII ) 259.97 275.68 196.63 989.29 524.70 652.46 X Other Comprehensive Income A ( i ) Items that will not be reclassified to profit or loss - -Actuarial gain / ( loss ) 0.59 ( 0.45 ) ( 0.61 ) ( 1.17 ) ( 4.57 ) ( 7.21 ) ( ii ) Income tax relating to items that will not be reclassified ( 0.10 ) 0.08 0.11 0.21 0.80 1.25 to profit or loss B ( i ) Items that will be reclassified to profit or loss - Exchange difference in translating the financial statement of foreign operation ( 0.19 ) ( 0.12 ) 0.23 ( 0.18 ) 0.02 ( 0.60 ) - Gain / ( loss ) on cash flow hedge 0.30 0.18 0.12 0.51 ( 0.71 ) ( 1.47 ) ( ii ) Income tax relating to items that will be reclassified to ( 0.02 ) ( 0.01 ) ( 0.04 ) ( 0.06 ) 0.12 0.36 profit or loss Other Comprehensive Income / ( Loss ) for the period net of tax ( X ) 0.58 ( 0.32 ) ( 0.19 ) ( 0.69 ) ( 4.34 ) ( 7.67 ) xxūww XI Total Comprehensive Income for the period ( IX + X ) 260.55 275.36 196.44 988.60 520.36 644.79 XII Paid - up equity share capital ( Face value of 2 / - each ) 25.37 25.37 25.27 25.37 25.27 25.27 XIII Other Equity 3640.33 11.94 XIV Share Warrant 3677.54 XV Net Worth XVI Earnings per share ( of 2 / - each ) ( Not annualised ) : Basic ( ) 20.49 21.79 15.56 78.16 41.53 51.64 Diluted ( ) 20.49 21.79 15.56 78.16 41.51 51.60 Laboratories Трса Limited